Veeva Systems Partners with Amgen to Enhance Clinical Trial Efficiency with Cloud Solutions
ByAinvest
Thursday, Aug 28, 2025 8:11 am ET1min read
AMGN--
Veeva Systems, known for its comprehensive suite of cloud software, data, and business consulting services, offers solutions tailored to the unique needs of life sciences companies. The company's three main product categories—Veeva Development Cloud, Veeva Commercial Cloud, and Veeva Data Cloud—provide robust solutions for clinical trial execution, commercialization, and data management respectively [1].
The collaboration with Amgen is set to optimize clinical trial processes by integrating Veeva's cloud solutions with Amgen's operational systems. This integration is expected to enhance data accuracy, streamline workflows, and improve overall operational efficiency. The use of Veeva's AI-driven tools, such as Veeva AI Agents, will further enable predictive analytics and automated data synthesis, potentially reducing trial costs and accelerating time-to-market [2].
The partnership reflects a broader industry trend towards ecosystem-based innovation, where shared data and AI capabilities become competitive advantages. By leveraging Veeva's extensive experience in life sciences and Amgen's expertise in clinical trials, the collaboration is poised to set new standards in the industry [3].
For investors, this partnership underscores Veeva's strategic agility and commitment to digital transformation. The company's pivot from a Salesforce-dependent CRM provider to a self-sustaining cloud leader, combined with its ability to integrate with major pharmaceutical firms like Amgen, positions Veeva for significant growth. The collaboration is expected to contribute to Veeva's goal of achieving $6 billion in revenue by 2030 [4].
In conclusion, the Veeva-Amgen partnership is a significant step towards enhancing operational efficiency and innovation in the life sciences industry. By harnessing the power of cloud solutions and AI, the collaboration promises to deliver tangible benefits to both companies and their customers. As the industry continues to grapple with rising R&D costs and regulatory pressures, such strategic partnerships are likely to become increasingly important [5].
References:
[1] https://www.veeva.com/products/vault-platform/
[2] https://www.ainvest.com/news/veeva-systems-unlocking-commercial-cloud-ai-synergies-iqvia-partnership-2508/
[3] https://www.veeva.com/products/vault-platform/
[4] https://www.ainvest.com/news/veeva-systems-unlocking-commercial-cloud-ai-synergies-iqvia-partnership-2508/
[5] https://www.veeva.com/products/vault-platform/
VEEV--
Veeva Systems has collaborated with Amgen to streamline clinical trials using its cloud solutions. Veeva offers a range of cloud software, data, and business consulting services designed to meet the needs of life sciences companies from R&D to commercialization. The company's three product categories include Veeva Development Cloud, Veeva Commercial Cloud, and Veeva Data Cloud, which provide solutions for clinical trial execution, commercialization, and data management.
Veeva Systems has announced a strategic partnership with Amgen to leverage its cloud solutions for streamlining clinical trials. This collaboration aims to enhance efficiency and data management in the life sciences sector, a critical area for pharmaceutical companies seeking to accelerate drug development and commercialization.Veeva Systems, known for its comprehensive suite of cloud software, data, and business consulting services, offers solutions tailored to the unique needs of life sciences companies. The company's three main product categories—Veeva Development Cloud, Veeva Commercial Cloud, and Veeva Data Cloud—provide robust solutions for clinical trial execution, commercialization, and data management respectively [1].
The collaboration with Amgen is set to optimize clinical trial processes by integrating Veeva's cloud solutions with Amgen's operational systems. This integration is expected to enhance data accuracy, streamline workflows, and improve overall operational efficiency. The use of Veeva's AI-driven tools, such as Veeva AI Agents, will further enable predictive analytics and automated data synthesis, potentially reducing trial costs and accelerating time-to-market [2].
The partnership reflects a broader industry trend towards ecosystem-based innovation, where shared data and AI capabilities become competitive advantages. By leveraging Veeva's extensive experience in life sciences and Amgen's expertise in clinical trials, the collaboration is poised to set new standards in the industry [3].
For investors, this partnership underscores Veeva's strategic agility and commitment to digital transformation. The company's pivot from a Salesforce-dependent CRM provider to a self-sustaining cloud leader, combined with its ability to integrate with major pharmaceutical firms like Amgen, positions Veeva for significant growth. The collaboration is expected to contribute to Veeva's goal of achieving $6 billion in revenue by 2030 [4].
In conclusion, the Veeva-Amgen partnership is a significant step towards enhancing operational efficiency and innovation in the life sciences industry. By harnessing the power of cloud solutions and AI, the collaboration promises to deliver tangible benefits to both companies and their customers. As the industry continues to grapple with rising R&D costs and regulatory pressures, such strategic partnerships are likely to become increasingly important [5].
References:
[1] https://www.veeva.com/products/vault-platform/
[2] https://www.ainvest.com/news/veeva-systems-unlocking-commercial-cloud-ai-synergies-iqvia-partnership-2508/
[3] https://www.veeva.com/products/vault-platform/
[4] https://www.ainvest.com/news/veeva-systems-unlocking-commercial-cloud-ai-synergies-iqvia-partnership-2508/
[5] https://www.veeva.com/products/vault-platform/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet